



Reg.no. 1989/001987/07

LUNDBECK AND ABILIFY

We are delighted to announce that Lundbeck will be solely responsible for the marketing of ABILIFY tablets as from 1 September 2016.

Lundbeck has been involved in the research and development of drugs for psychiatric illnesses for more than 60 years, particularly in psychotic illnesses and mood disorders.

It is with this heritage and experience that we will be adding ABILIFY tablets to our portfolio of antipsychotic drugs.

Lundbeck has strongly supported patient and doctor education and fully intends to carry this forward with ABILIFY in the field of Bipolar disorder and Schizophrenia.

ABILIFY has proven efficacy in:

- Clinical improvement in adults with acute manic episodes in Bipolar 1 Disorder
- Prevention of recurrence of new manic episodes in patients who have previously responded to ABILIFY therapy
- The treatment of Schizophrenia and maintenance of clinical improvement in adults

ABILIFY has a favourable tolerability profile and has been used worldwide and in South African since its launch in 2002.

Please contact your Lundbeck Representative or Elaine Milne on 011 699 1600 for any further information.

Assuring you of our ongoing support.

Kind Regards

Elaine Milne
Marketing Manager

